Skip to content

Does Intense Regimented Surveillance Improve the Rates of Therapeutic Re-Intervention After Lung Cancer Surgery

Does Intense Regimented Surveillance Improve the Rates of Therapeutic Re-Intervention After Lung Cancer Surgery: A Pilot Study for the Intense-CT Trial

Status
Completed
Phases
Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02149576
Acronym
Intense-CT
Enrollment
313
Registered
2014-05-29
Start date
2014-08-01
Completion date
2018-04-30
Last updated
2018-12-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lung Neoplasms

Keywords

Retrospective Review, Pilot Study, Early Stage NSCLC, Post-Surgical Surveillance, Re-intervention Rates

Brief summary

After curative lung cancer surgery, there is a risk of recurrence of the primary cancer, or development of a new cancer. Historically, patients who have undergone curative lung cancer surgery have been monitored with chest radiographs (CXR). Unfortunately, 70% of such patients still die of lung cancer. As a result, there has been interest in other methods of surveillance in order to detect recurring or new cancers earlier and have more success in treating them. One such technique is Low Dose Computed Tomography (LDCT), which is currently the standard of care and surveillance at this institution. This pilot study aims to determine whether regimented, intensive, short interval LDCT surveillance leads to higher rates of detection and treatment of recurring lung cancers. The study group will be followed up according to a regimented surveillance program using LDCT. The study group will be compared to a group of historical controls whose follow up after surgery was not standardized, but rather left up to the discretion of the individual surgeon. If the results of this study show improvements in detection and treatment of recurrent cancers, it will allow for a larger trial to study the effects of the LDCT surveillance program on lung cancer survival. The study question aims to determine whether for survivors after curative surgery for Stage I and Stage II lung cancer, a structured Surveillance Program with Low Dose CT can increase the rate of detection and treatment of recurring or new cancers when compared to historical non-structured surveillance with CXR. This study will also determine if it is warranted to pursue a larger scale randomized controlled trial to further investigate optimal LDCT surveillance follow-up intervals and long-term lung cancer survival.

Interventions

PROCEDURELow Dose Computed Tomography Imaging
PROCEDUREChest Radiograph Imaging

Sponsors

McMaster Surgical Associates
CollaboratorOTHER
McMaster University
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SCREENING
Masking
SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Patients must be at minimum 18 years of age * Patients must have undergone complete resection for pathological Stage I or Stage II lung cancer * Patients must demonstrate the ability to understand English * Patients must be able to demonstrate aptitude and willingness to comply with describes study procedures

Exclusion criteria

* Patients with residual gross or microscopic disease after surgery * Patients with pathological Stage III or Stage IV lung cancer

Design outcomes

Primary

MeasureTime frameDescription
Rate of therapeutic re-intervention within the first year after curative resection of lung cancerOne year after surgeryDefined by: 1) rate of curative intent radiation treatment after detection of recurrent or new primary lung cancer 2) rate of curative intent reoperation after detection of recurrent or new primary lung cancer. Measured by frequency of events.

Secondary

MeasureTime frameDescription
Rate of adherence to follow-up visitsOne year after surgeryMeasured by frequency of events
Morbidity of associated interventionsOne year after surgeryMeasured by frequency of events

Countries

Canada

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026